Abstract
Patients with HR NB (∼50% of patients with NB at initial diagnosis) and limited or no response to initial therapy have poor outcomes, and residual disease can drive relapse. Naxitamab is a GD2-binding monoclonal antibody, recently approved in the US in combination with granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of relapsed/refractory (R/R) HR NB in the bone and/or bone marrow (BM) in patients ≥1 year of age with a partial response, minor response, or stable disease to prior therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
